Related Experiment Video

Updated: Aug 17, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Anti-angiogenic therapies in cancer clinical trials

H T Zhang1, A L Harris

  • 1Molecular Oncology Laboratories, Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed

Insights

Anti-angiogenesis and vascular targeting therapies show promise for cancer treatment. This review examines 30 agents in clinical trials, addressing challenges in patient assessment, trial design, toxicity, and resistance.

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Development

Background:

  • Vascular-targeting strategies are recognized for therapeutic potential in cancer and other diseases.
  • Preclinical and early clinical data suggest anti-angiogenesis and vascular targeting hold significant promise as major clinical therapies.

Purpose of the Study:

  • To review approximately 30 anti-angiogenic and vascular targeting agents currently in cancer clinical trials.
  • To highlight challenges in assessing the activity of these agents in patients.
  • To discuss issues related to trial design, potential toxicities, and resistance mechanisms.

Main Methods:

  • Review of approximately 30 anti-angiogenic and vascular targeting agents in cancer clinical trials.
  • Analysis of existing evidence regarding therapeutic potential.
  • Identification of problems in clinical assessment, trial design, toxicity, and resistance.

Main Results:

  • A significant number of agents are under investigation in clinical trials.
  • Challenges exist in evaluating the efficacy and safety of these agents in patient populations.
  • Potential toxicities and the development of resistance mechanisms are key concerns.

Conclusions:

  • Anti-angiogenesis and vascular targeting represent a promising frontier in cancer therapy.
  • Addressing challenges in clinical trial design and patient assessment is crucial for successful implementation.
  • Understanding and overcoming resistance mechanisms are vital for long-term therapeutic success.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...